Answers are grounded in this paper and cite their sources.
INTRODUCTION: The optimal timing of radiotherapy (RT) for asymptomatic brain metastasis (aBM) in patients with non-small cell lung cancer (NSCLC) without targetable oncogenic drivers treated with immune checkpoint inhibitors (ICIs) remains unclear. This study aimed to assess the efficacy and safety of upfront (U)-RT combined with ICIs for aBM. METHODS: We retrospectively reviewed consecutive patients with aBM from NSCLC who received ICI-containing chemotherapy at National Cancer Center Hospital East between 2016 and 2021. The U-RT group was defined patients who received RT for aBM before or during the first ICI cycle, and the non-U-RT group otherwise. RESULTS: Of the 324 patients with NSCLC and aBM screened, 54 were enrolled, with 34 and 20 patients in the U-RT and non-U-RT groups, respectively. The median overall survival was 27.5 and 13.8 months (hazard ratio [HR] = 0.40, 95 % confidence interval [CI] 0.19-0.87), respectively, and median cranial progression-free survival was 9.2 and 6.0 months (HR = 0.50, 95 % CI 0.25-0.98), respectively, in the U-RT and non-U-RT groups. The U-RT group showed a significantly lower aBM progression rate than the non-U-RT group (P = 0.04). U-RT was an independent prognostic factor in the multivariate analysis using propensity score adjustment (HR = 0.42, 95 % CI 0.18-0.96). Although severe adverse events were observed in 47 % and 35 % of patients in the U-RT and non-U-RT groups, respectively, no treatment-related deaths occurred. CONCLUSIONS: ICIs with U-RT demonstrated higher efficacy with acceptable tolerability for aBM than ICIs without U-RT. Our findings should be confirmed in future prospective trials.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: